MedTrace Logo

Effect of HMP on Diabetic Microangiopaemia in T2DM

NCT05095922 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-07-09

No results posted yet for this study

Summary

The study mainly investigates the therapeutic effect of Heart-Protecting Musk Pill (HMP) on patients with diabetic microangiopathy. According to the indicators of diabetic nephropathy (DN), diabetic retinopathy (DR), oxidative stress and inflammatory factor in patients with diabetic microvascular disease after using HMP, the investigators aim to evaluate the effect of HMP on diabetic microangiopathy, oxidative stress and inflammation.

Conditions

  • Diabetes Mellitus, Type 2
  • Diabetic Angiopathies

Interventions

DRUG

Heart-Protecting Musk Pill

Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)

DRUG

Valsartan Capsules

Valsartan Capsules(capsule, 80mg, once a day, 3 months）

DRUG

Calcium Dobesilate Capsules

Calcium Dobesilate Capsules(capsule, 500mg, three times a day, 3 months)

Sponsors & Collaborators

  • Affiliated Hospital of Nantong University

    lead OTHER

Principal Investigators

  • Xinlei Wang · Affiliated Hospital of Nantong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2024-05-30
Completion
2024-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095922 on ClinicalTrials.gov